This is being deposited with the United States Patent Office via the "Electronic Filing System" service under 37 CFR 1.10 on the date indicated below and is addressed to

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On April 14, 2006

MORGAN, LEWIS and BOCKIUS LLP

By: /Kathryn A. Degliantoni/

Kathryn A. Degliantoni

PATENT
Attorney Docket No.: 061877-5001-US
Client Ref. No.: P1081US10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation Number: 9439
He, Yun *et al.*	Examiner: Saeed, Kamal
Application No.: 10/690,802	Technology Center/Art Unit: 1626
Filed: October 21, 2003	RESPONSE TO RESTRICTION REQUIREMENT
For: OXINDOLES WITH ANTI-HIV ACTIVITY	
Customer No.: 47930	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated March 24, 2006, please enter the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page **2** of this paper.

Remarks/Arguments begin on page **7** of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Previously presented) A compound having the formula:



wherein

R^1, R^2, R^3 and R^4 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, OR^8, NO_2, CN and halogen

wherein

R^8 is a member selected from H and substituted or unsubstituted alkyl;

R^5 and $R^{5'}$ are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, SR^9 and $C(O)R^9$

wherein

R^9 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, $NR^{10}R^{11}$ and OR^{11}

wherein

R^{10} is a member selected from H, substituted or unsubstituted alkyl and OR^{12}

wherein

R^{12} is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R^{11} is a member selected from H, $C(O)R^{13}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycloalkyl, and wherein R^{10} and R^{11}, together with the nitrogen to which they are bound, are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 3 to 7 members

wherein

R^{13} is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and $NR^{14}R^{15}$

wherein

R^{14} and R^{15} are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R^6 and $R^{6'}$ are members independently selected from H, substituted or unsubstituted alkyl and $C(O)R^{16}$;

wherein

R^{16} is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, $NR^{17}R^{18}$ and OR^{17}

wherein

R^{17} and R^{18} are members independently selected from H, substituted or unsubstituted alkyl, substituted or

unsubstituted heteroalkyl and substituted or unsubstituted aryl; and

R^7 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.

2. (Previously presented) The compound according to claim **1**, wherein at least one of R^5 and $R^{5'}$ is a member selected from substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted furanyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted quinolinyl, and substituted or unsubstituted thienyl.

3. (Previously presented) The compound according to claim **1**, wherein at least one of R^{10} and R^{11} is substituted or unsubstituted C_1-C_6 alkyl.

4. (Previously presented) The compound according to claim **1**, wherein at least one of R^6 and $R^{6'}$ is a member selected from substituted or unsubstituted C_1-C_6 alkyl.

5. (Previously presented) The compound according to claim **1**, having the formula:



.

6. (Previously presented) The compound according to claim **5**, having the formula:



.

7. (Previously presented) The compound according to claim **6**, wherein R^{11} is substituted or unsubstituted C_1-C_4 alkyl.

8. (Previously presented) The compound according to claim **5**, wherein at least one of R^5 and $R^{5'}$ is a member selected from substituted and unsubstituted:



9. (Previously presented) The compound according to claim **5**, wherein R^6 and $R^{6'}$ are independently selected from substituted or unsubstituted methyl and substituted or unsubstituted ethyl.

10. (Previously presented) A pharmaceutical formulation comprising a compound according to claim **1** and a pharmaceutically acceptable carrier.

11. (Previously presented) A method of inhibiting HIV in a cell, said method comprising contacting said cell with an amount of a compound according to claim **1** sufficient to inhibit said HIV.

12. (Previously presented) A method of inhibiting reverse transcriptase in a cell, said method comprising contacting said cell with an amount of a compound according to claim **1** sufficient to inhibit said reverse transcriptase.

13. (Previously presented) The method according to claim **11**, wherein said cell is in a human.

14. (Previously presented) The method according to claim **12**, wherein said cell is in a human.

15. (Previously presented) A method of treating HIV infection in a human subject comprising administering to said subject an amount of a compound according to claim **1**, sufficient to treat said HIV infection.

16. (Previously presented) A method of providing prophylaxis against HIV infection comprising administering a prophylactic amount of a compound according to claim **1** to a person who is at risk of HIV infection.

17. (Previously presented) The method according to claim **15**, wherein said HIV is a drug resistant mutant.